MBHB Partner Kevin Noonan on how the Teva Orange Book Defeat is impacting pharma patent strategy in Bloomberg Law

In Bloomberg Law, MBHB Partner Kevin Noonan discusses how the Federal Circuit’s ruling to delist Teva in the Orange Book is impacting pharma patent strategy, suggesting that moving forward companies will need to be cognizant of the regulatory risks when drafting patent claims. View the article here.